The aim of this study was to compare a contralateral routing of signal (CROS) hearing aid to a transcutaneous bone-anchored device in the same conditions. This prospective crossover study included 18 adult patients with a single-sided deafness (SSD). After a trial period of 60 days with CROS and 7 days with a transcutaneous bone-anchored device (Alpha 1®, Sophono, Boulder, Colo., USA) on a headband, 13 (72%) patients opted for Alpha 1, 2 patients for CROS, and 3 rejected both rehabilitation methods. Clinical tolerance, satisfaction, hearing performances (pure-tone audiometry, speech test in quiet and in noise, stereo audiometry, sound localization, and Hearing in Noise Test), and quality of life (Glasgow Benefit Inventory, Abbreviated Profile of Hearing Aid Benefit and Glasgow Hearing Aid Benefit questionnaires) were measured at 3 and 12 months after the implantation. Both devices improved equally the hearing in noise and the quality of life. Transcutaneous devices represent an effective option in SSD.

Agterberg MJH, Hol MKS, Van Wanrooij MM, Van Opstal AJ, Snik AFM: Single-sided deafness and directional hearing: contribution of spectral cues and high-frequency hearing loss in the hearing ear. Front Neurosci 2014;8:188.
Arndt S, Aschendorff A, Laszig R, Beck R, Schild C, Kroeger S, et al: Comparison of pseudobinaural hearing to real binaural hearing rehabilitation after cochlear implantation in patients with unilateral deafness and tinnitus. Otol Neurotol 2011;32:39-47.
Arunachalam PS, Kilby D, Meikle D, Davison T, Johnson IJ: Bone-anchored hearing aid quality of life assessed by Glasgow Benefit Inventory. Laryngoscope 2001;111:1260-1263.
Bance M, Abel SM, Papsin BC, Wade P, Vendramini J: A comparison of the audiometric performance of bone anchored hearing aids and air conduction hearing aids. Otol Neurotol 2002;23:912-919.
Bishop CE, Eby TL: The current status of audiologic rehabilitation for profound unilateral sensorineural hearing loss. Laryngoscope 2010;120:552-556.
Bosman AJ, Hol MKS, Snik AFM, Mylanus EAM, Cremers CWRJ: Bone-anchored hearing aids in unilateral inner ear deafness. Acta Otolaryngol 2003;123:258-260.
Cass SP, Mudd PA: Bone-anchored hearing devices: indications, outcomes, and the linear surgical technique. Oper Tech Otolaryngol Head Neck Surg 2010;21:197-206.
Cox RM: Administration and application of the APHAB. Hear J 1997;50:32-48.
Doshi J, Sheehan P, McDermott AL: Bone anchored hearing aids in children: an update. Int J Pediatr Otorhinolaryngol 2012;76:618-622.
Denoyelle F, Leboulanger N, Coudert C, Mazzaschi O, Loundon N, Vicaut E, et al: New closed skin bone-anchored implant: preliminary results in 6 children with ear atresia. Otol Neurotol 2013;34:275-281.
Firszt JB, Holden LK, Reeder RM, Waltzman SB, Arndt S: Auditory abilities after cochlear implantation in adults with unilateral deafness: a pilot study. Otol Neurotol 2012;33:1339-1346.
Gatehouse S: Glasgow Hearing Aid Benefit Profile: Derivation and validation of a client-centered outcome measure for hearing-aid services. J Am Acad Audiol 1999;10:80-103.
Giolas TG, Wark DJ: Communication problems associated with unilateral hearing loss. J Speech Hear Disord 1967;32:336-343.
Håkansson B, Tjellström A, Rosenhall U: Hearing thresholds with direct bone conduction versus conventional bone conduction. Scand Audiol 1984;13:3-13.
Hol MKS, Kunst SJW, Snik AFM, Bosman AJ, Mylanus EAM, Cremers CWRJ: Bone-anchored hearing aids in patients with acquired and congenital unilateral inner ear deafness (Baha CROS): clinical evaluation of 56 cases. Ann Otol Rhinol Laryngol 2010;119:447-454.
House JW, Kutz JW: Bone-anchored hearing aids: incidence and management of postoperative complications. Otol Neurotol 2007;28:213-217.
Kitterick PT, O'Donoghue GM, Edmondson-Jones M, Marshall A, Jeffs E, Craddock L, et al: Comparison of the benefits of cochlear implantation versus contra-lateral routing of signal hearing aids in adult patients with single-sided deafness: study protocol for a prospective within-subject longitudinal trial. BMC Ear Nose Throat Disord 2014;14:7.
Lin LM, Bowditch S, Anderson MJ, May B, Cox KM, Niparko JK: Amplification in the rehabilitation of unilateral deafness: speech in noise and directional hearing effects with bone-anchored hearing and contralateral routing of signal amplification. Otol Neurotol 2006;27:172-182.
McDermott AL, Williams J, Kuo M, Reid A, Proops D: The Birmingham pediatric bone-anchored hearing aid program: a 15-year experience. Otol Neurotol 2009;30:178-183.
Riss D, Arnoldner C, Baumgartner WD, Blineder M, Flak S, Bachner A, Gstoettner W, Hamzavi JS: Indication criteria and outcomes with the Bonebridge transcutaneous bone-conduction implant. Laryngoscope 2014;124:2802-2806.
Robinson K, Gatehouse S, Browning GG: Measuring patient benefit from otorhinolaryngological surgery and therapy. Ann Otolog Rhinol Laryngol 1996;105:415-422.
Ryu NG, Moon IJ, Byun H, Jin SH, Park H, Jang KS, et al: Clinical effectiveness of wireless CROS (contralateral routing of offside signals) hearing aids. Eur Arch Otorhinolaryngol 2014, DOI: 10.1007/s00405-014-3133-0.
Saroul N, Gilain L, Montalban A, Giraudet F, Avan P, Mom T: Patient satisfaction and functional results with the bone-anchored hearing aid (BAHA). Eur Ann Otorhinolaryngol Head Neck Dis 2011;128:107-113.
Siegert R: Partially implantable bone conduction hearing aids without a percutaneous abutment (Otomag): technique and preliminary clinical results. Adv Otorhinolaryngol 2011;71:41-46.
Tjellström A, Granström G: Long-term follow-up with the bone-anchored hearing aid: a review of the first 100 patients between 1977 and 1985. Ear Nose Throat J 1994;73:112-114.
Tjellström A, Lindström J, Hallén O, Albrektsson T, Brånemark PI: Osseointegrated titanium implants in the temporal bone. A clinical study on bone-anchored hearing aids. Am J Otol 1981;2:304-310.
Vaneecloo FM, Ruzza I, Hanson JN, Gérard T, Dehaussy J, Cory M, et al: The monaural pseudo-stereophonic hearing aid (BAHA) in unilateral total deafness: a study of 29 patients (in French). Rev Laryngol Otol Rhinol (Bord) 2001;122:343-350.
Vermeire K, Van de Heyning P: Binaural hearing after cochlear implantation in subjects with unilateral sensorineural deafness and tinnitus. Audiol Neurotol 2009;14:163-171.
Verstraeten N, Zarowski AJ, Somers T, Riff D, Offeciers EF: Comparison of the audiologic results obtained with the bone-anchored hearing aid attached to the headband, the testband, and to the ‘snap' abutment. Otol Neurotol 2009;30:70-75.
Wazen JJ, Spitzer JB, Ghossaini SN, Fayad JN, Niparko JK, Cox K, et al: Transcranial contralateral cochlear stimulation in unilateral deafness. Otolaryngol Head Neck Surg 2003;129:248-254.
Welsh LW, Welsh JJ, Rosen Lf, Dragonnette JE: Functional impairments due to unilateral deafness. Ann Otol Rhinol Laryngol 2004;113:987-993.
Wie OB, Pripp AH, Tvete O: Unilateral deafness in adults: effects on communication and social interaction. Ann Otol Rhinol Laryngol 2010;119:772-781.
Yu JKY, Wong LLN, Tsang WSS, Tong MCF: A tutorial on implantable hearing amplification options for adults with unilateral microtia and atresia. Biomed Res Int 2014;2014:703256.
Zawawi F, Kabbach G, Lallemand M, Daniel SJ: Bone-anchored hearing aid: why do some patients refuse it? Int J Pediatr Otorhinolaryngol 2014;78:232-234.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.